earnings
confidence high
sentiment negative
materiality 0.75
Biogen expects ~$222M pre-tax charge in Q4 2025 for IPR&D and milestone costs; EPS impact ~$1.26
BIOGEN INC.
2025-FY EPS
reported $8.79
vs consensus $1.65
▲ beat
(+433.9%)
- Q4 2025 acquired IPR&D, upfront and milestone expense estimated at ~$222M pre-tax.
- Estimated impact of $1.26 per diluted share on both GAAP and non-GAAP EPS.
- Expense line item newly presented separately since Q1 2025.
- Final Q4 2025 results not finalized; subject to closing procedures.
- Company does not forecast such expenses due to uncertainty in timing and magnitude.